Biotech Daily Dose


Flexion-092217.jpg Shares of Flexion Therapeutics Inc. (FLXN) are up 40% so far this year, well ahead of the iShares NASDAQ Biotech Index ETF (IBB), which has returned only 25% during the same period.

pharma-092117.jpg Today's Daily Dose brings you news about Acceleron Pharma's public offering; pre-market approval of Abiomed's Impella RP heart pump; FDA panel review of Aerie's Rhopressa; NASDAQ notification for Intellipharmaceutics; positive data from Karyopharm's phase II/III SEAL study and Pfizer's suit against Johnson & Johnson.

Pharma-091417.jpg Today's Daily Dose brings you news about Biohaven's collaboration with Alzheimer's Disease Cooperative Study; CHMP positive opinion on GlaxoSmithKline's Trelegy Ellipta and TESARO's ZEJULA; Orphan Drug designated Motif's investigational drug candidate, Iclaprim, and FDA approval of Neos' third extended release product for the treatment of ADHD.

Logos-Pharma-091517.jpg Halozyme Therapeutics Inc. (HALO) touched a new 52-week high on Thursday, rising as much as 24%, following deals with Bristol-Myers Squibb Co. (BMY) and Swiss drug giant Roche AG involving its ENHANZE drug-delivery technology.

Pharma-091417.jpg Today's Daily Dose brings you news about encouraging interim analysis of Alexion's REGAIN study of Soliris; Fennec's uplisting and preliminary results of SIOPEL 6; Amicus' failed epidermolysis bullosa trial; Vanda's disappointing atopic dermatitis trial results and FDA panel's recommendation for approval of GlaxoSmithKline's investigational shingles vaccine Shingrix.

Pharma-091317.jpg Today's Daily Dose brings you news about regulatory catalysts awaiting Astellas, KemPharm and Sorrento; Aldeyra's positive phase IIa clinical trial results in dry eye disease; Inotek's merger with Rocket Pharmaceuticals and Zafgen's progress in phase II trial of ZGN-1061 in type 2 diabetes.

Pharma-091217.jpg Today's Daily Dose brings you news about AbbVie's SELECT-BEYOND trial results; Aldeyra's clinical trial catalyst to watch out for today; Fennec's uplisting; Peregrine's quarterly results; Pulse Bio's withdrawal of 510(k) for PulseTx System and appointment of a new CEO at TEVA.

Pharma-090817.jpg Today's Daily Dose brings you news about Array's encouraging results from phase III melanoma study; AstraZeneca's newfound hope in Imfinzi in lung cancer setting; Blueprint's ongoing phase I trial of BLU-554 in advanced hepatocellular carcinoma; Bristol-Myers' CheckMate -238 trial and Immune Design's soft tissue sarcoma trial results.

Pharma-090817.jpg Today's Daily Dose brings you news about Amgen's chronic migraine study; Ampio's non compliance with certain listing standards of NYSE; Kura's phase II trial of Tipifarnib; Adamas' phase Ib epilepsy trial and AbbVie's phase IIb dose-ranging study of Upadacitinib in atopic dermatitis.

Pharma-090617.jpg Today's Daily Dose brings you news about Atara's orphan drug status for its drug candidate ATA230; Bellerophon's positive top line data from phase II trial of INOpulse; BioCryst's encouraging phase II hereditary angioedema trial results and Bio-Techne's acquisition of Trevigen.

Pharma-083117.jpg Today's Daily Dose brings you news about encouraging preliminary data of Immune Design's phase II trial of CMB305 in soft tissue sarcoma; Novartis scripting history - with the FDA approval of its CAR-T therapy; FDA approval of Medicines Co.'s VABOMERE and Teva's AUSTEDO and disappointing results from Otonomy's phase III clinical trial of OTIVIDEX.

Pharma-083017.jpg Today's Daily Dose brings you news about Apricus' resolve to get its investigational erectile dysfunction product approved by the FDA; special status granted to Abeona's investigational Epidermolysis Bullosa treatment; upcoming regulatory catalyst of BioMarin and Pfizer; Nasdaq notification for Immune Pharma; ProQR Therapeutics' near-term clinical trial catalyst and Sorrento's second try at gettin

FDA-decision-082817.jpg As we head into another month of new drug approvals, let's check out the FDA decisions coming up in September.

Pharma-082917.jpg Today's Daily Dose brings you news about Kamada's proposed phase III trial for inhaled Alpha-1 Antitrypsin (AAT) therapy; cost-effectiveness of EnteroMedics' vBloc therapy for obesity; Bristol-Myers and Daiichi Sankyo's partnership; Nasdaq's warning for Biostar Pharma; La Jolla's and Roche's upcoming regulatory catalysts, and approval of Tandem Diabetes' sensor-augmented insulin pump.

Accelerate-Tech-082517.jpg Shares of Accelerate Diagnostics Inc. (AXDX) trade around $22, about 27% down from their 52-week high of $30.45 recorded on June 23, 2017.

Follow RTT